1/21/2024 0 Comments Nasdaq codxThis also beats out the nasal swab tests which is the common method for self-administered testing and only has a 55% detection rate. With this approach, the CRL test has achieved 100% sensitivity and specificity, making it the most accurate saliva-based test. The patient essentially spits into a tube and sends it in. The saliva test can be administered anywhere - in the home, schools, workplace, etc.The advantages of the Co-Primer test, which should also be attractive for international customers, is that Co-Diagnostics is already marketing its test internationally and are already on the ground in India (3 rd in confirmed cases) with its joint venture, CoSara. The continued unmet need in testing is across the country and globe the US is not alone and demand is expected to increase with the pandemic now nearing 5M infections in the U.S with no signs of slowing down.Clinical Reference Labs (CRL) is using the Company’s COVID-19 test already and is now expanding to saliva collection with EUA for OraSure's OMNIgene Oral Device for saliva collection. The Company is directly involved with this as a US testing provider and is involved with two recently approved saliva collection methods: Saliva-based testing is now the mix- Essentially swish, spit, and ship it off to the lab. Some key highlights of the Maxim report include: With COVID cases on the rise in the US and around the globe, and testing times increasing past the point of usefulness, interest in expanding testing capacity has increased markedly. That same day, the analyst from Maxim Group reiterated a Buy status and $30 PT on the Company’s stock. CODX shares were up 28% on the news before seeing some profit taking on Tuesday.ĬRL declared that the test has demonstrated 100% sensitivity/specificity (higher than any other saliva-based molecular test for COVID-19) and can be processed within 24-48 hours, which is important considering that in many cases current tests are taking up to a week or more to return results. The test uses Co-Diagnostics probes and primers. (NASDAQ: CODX) (the Company), a molecular diagnostics company with a unique, patented diagnostics testing platform, announced that its partner, Clinical Reference Laboratory (CRL), one of the largest testing providers in the country, had received Emergency Use Authorization (EUA) from the FDA for a self-collected, saliva-based PCR test for COVID-19. Maxim reiterate Buy with a price target of $30Įarlier this week, Co-Diagnostics, Inc. 05, 2020 (GLOBE NEWSWIRE) - Saliva-Based Test Powered by Co-Diagnostics (NASDAQ: CODX) a Game Changer Past performance is a poor indicator of future performance.New York City, Aug. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on or relating to the use of, or inability to use, or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. Under no circumstances does any information posted on represent a recommendation to buy or sell a security. Is not operated by a broker, a dealer, or a registered investment adviser. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The firm uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis, a drug resistant tuberculosis test, hepatitis B and C, Malaria, dengue, human immunodeficiency virus and Zika virus, all of which tests have been designed and validated in its laboratory. The company also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid. The firm is engaged in developing, manufacturing and marketing diagnostics technology. The company is headquartered in Salt Lake City, Utah and currently employs 101 full-time employees. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |